标普和纳斯达克内在价值 联系我们

Fresh Tracks Therapeutics, Inc. FRTX NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
53/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Fresh Tracks Therapeutics, Inc. (FRTX) .

本页证实的标准:

  • VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。

SharesGrow 综合评分: 51/100 其中 2/7 项标准通过。

SharesGrow 7-Criteria Score
53/100
SG Score
View full scorecard →
价值
N/A
No coverage
未來
100/100
Analyst consensus
→ Forecast
过去
0/100
→ Income
~
健康
67/100
Debt-to-Equity & liquidity
→ Health
~
护城河
50/100
→ Income
成长
90/100
→ Income
收入
10/100
→ Income

估值概览 — FRTX

估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.69
EV/EBITDA0.0
每股数据
EPS (TTM)$-0.96
每股账面价值$0.00
每股营收$1.35
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%

EPS:实际 vs 预期

P/E Ratio & Earnings Yield

每股收益 (EPS) 历史

Year EPS(稀释) 营收 净利润 净利润率
2014 $-585.11 $15.22M $-16.49M -108.4%
2015 $-317.17 $20.95M $-9.24M -44.1%
2016 $-282.12 $14.53M $-8.97M -61.8%
2017 $-316.76 $13.82M $-12.96M -93.8%
2018 $-234.41 $1.62M $-16.25M -1002.1%
2019 $-386.21 $7.92M $-25.95M -327.7%
2020 $-38.37 $1.82M $-20.9M -1147.3%
2021 $-22.14 $404K $-39.52M -9782.4%
2022 $-7.36 $6.94M $-20.66M -297.6%
2023 $-0.96 $8.01M $-5.69M -71.1%
联系我们
🎓
SharesGrow 学院
学习如何计算内在价值,发现被低估的股票。
每周在线课程
给我们留言